B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
Mateos, M, Hari, P, Bahlis, N, Chari, A, Donk, NWCJ, Dholaria, B, Garfall, AL, Goldschmidt, H, Kortüm, KM, Krishnan, A, Martin, T, Morillo, D, Oriol, A, Reece, D, Rodriguez, C, Rodríguez‐Otero, P, San‐Miguel, JF, Usmani, SZ, Verona, R, Lin, SXW, Prior, TJ, Wade, M, Weiss, B, Goldberg, JD, Askari, E
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
Rodriguez‐Otero, P, Dholaria, B, Askari, E, Reece, D, Donk, N, Chari, A, Goldschmidt, H, Krishnan, A, Martin, T, Mateos, M, Morillo, D, Rodriguez, C, Rosinol, L, San‐Miguel, J, Balari, A, Wäsch, R, Weisel, K, Verona, R, Lin, S, Prior, T, Wade, M, Weiss, B, Goldberg, J, Oriol, A, Hari, P
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
Defining and treating high-risk multiple myeloma
Usmani, S Z, Rodriguez-Otero, P, Bhutani, M, Mateos, M-V, Miguel, J S
Published in Leukemia (01.11.2015)
Published in Leukemia (01.11.2015)
Get full text
Journal Article
P973: REAL‐WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT‐ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY
Weisel, K., Wadlund, A., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N., Rodriguez‐Otero, P.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON‐CELLULAR ANTI‐B‐CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
Donk, N., Mateos, M.‐V., Cohen, Y.C., Rodriguez‐Otero, P., Paiva, B., Cohen, A.D., Martin, T., Suvannasankha, A., Madduri, D., Corsale, C., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Deraedt, W., Roccia, T., Mistry, P., Xu, X., Li, K., Zudaire, E., Akram, M., Pacaud, L., Avivi, I., San‐Miguel, J.
Published in HemaSphere (09.05.2023)
Published in HemaSphere (09.05.2023)
Get full text
Journal Article
P1463: PHASE I DOSE ESCALATION OF LAVA‐051, A NOVEL BISPECIFIC GAMMA‐DELTA T‐CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES
Broijl, A., Donk, N., Bosch, F., Mateos, M. V., Rodriguez‐Otero, P., Tucci, A., Ghia, P., Adang, A., Parren, P., Tuinhof, I., Umarale, S., Winograd, B., Vliet, H., Kater, A.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P42 HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL‐1
Donk, N., Rasche, L., Touzeau, C., Chari, A., Schinke, C., Minnema, M., Berdeja, J., Oriol, A., Rodriguez‐Otero, P., Askari, E., Mateos, M., Costa, L., Caers, J., Krishnan, A., Vishwamitra, D., Ma, J., Qin, X., Gries, K.S., Kato, K., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J., Heuck, C., Moreau, P., San‐Miguel, J.
Published in HemaSphere (09.05.2023)
Published in HemaSphere (09.05.2023)
Get full text
Journal Article
P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON
Delforge, M., Usmani, S. Z., Donk, N. W., Garfall, A. L., Moreau, P., Oriol, A., Nooka, A. K., Rosinol, L., Bahlis, N., Rodriguez‐Otero, P., Martin, T., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Krishnan, A.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P13: CAN PATIENT‐REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
Popat, R, Badros, A, Kumar, S, Rodriguez‐Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
P1593: IMMUNE BIOMARKERS TO PREDICT SARS‐COV‐2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Tamariz‐Amador, L.‐E., Battaglia, A. M., Maia, C., Zherniakova, A., Guerrero, C., Zabaleta, A., Burgos, L., Botta, C., Fortuño, M.‐A., Alignani, D., Blanco, L., Grande, C., Manubens, A., Arguiñano, J.‐M., Gomez, C., Perez‐Persona, E., Olazabal, I., Oiartzabal, I., Panizo, C., Prosper, F., San Miguel, J. F., Rodriguez‐Otero, P., Martín‐Sánchez, E., Paiva, B., ASOVASNA, A. V.‐N. H.‐H.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Sanoja-Flores, L., Flores-Montero, J., Garcés, J. J., Paiva, B., Puig, N., García-Mateo, A., García-Sánchez, O., Corral-Mateos, A., Burgos, L., Blanco, E., Hernández-Martín, J., Pontes, R., Díez-Campelo, M., Millacoy, P., Rodríguez-Otero, P., Prosper, F., Merino, J., Vidriales, M. B., García-Sanz, R., Romero, A., Palomera, L., Ríos-Tamayo, R., Pérez-Andrés, M., Blanco, J. F., González, M., van Dongen, J. J. M., Durie, B., Mateos, M. V., San-Miguel, J., Orfao, A.
Published in Blood cancer journal (New York) (19.11.2018)
Published in Blood cancer journal (New York) (19.11.2018)
Get full text
Journal Article
S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY‐BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS
Rodriguez Otero, P., D'Souza, A., Reece, D., Donk, N. W., Chari, A., Krishnan, A., Martin, T., Mateos, M. V., Morillo, D., Hurd, D., Rosinol, L., Balari, A. S., Wäsch, R., Vishwamitra, D., Wang Lin, S. X., Prior, T., Vandenberk, L., Smit, M.‐A. D., Oriol, A., Dholaria, B.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
Rodriguez-Otero, P, Dholaria, B, Askari, E, Reece, D, van de Donk, N, Chari, A, Goldschmidt, H, Krishnan, A, Martin, T, Mateos, M, Morillo, D, Rodriguez, C, Rosinol, L, San-Miguel, J, Balari, A, Wäsch, R, Weisel, K, Verona, R, Lin, S, Prior, T, Wade, M, Weiss, B, Goldberg, J, Oriol, A, Hari, P
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE‐CEL, BB2121), A BCMA‐DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
Rodríguez‐Otero, P, Shah, N, Munshi, N, Berdeja, J, Jagannath, S, Finney, O, Martin, N, Agarwal, A, Rowe, E, Campbell, T, San‐Miguel, J
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
P21: SUBSEQUENT ANTI‐MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE‐CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
Rodríguez‐Otero, P, San‐Miguel, J, Anderson, LD, Lonial, S, Truppel‐Hartmann, A, Sanford, J, Rowe, E, Campbell, TB, Munshi, N
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE‐CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA‐3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
Rodríguez‐Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel‐Hartmann, A., Yang, Z., Favre‐Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.
Published in HemaSphere (09.05.2023)
Published in HemaSphere (09.05.2023)
Get full text
Journal Article
S180: RG6234, A NOVEL GPRC5D T‐CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST‐IN‐HUMAN TRIAL
Hasselbalch Riley, C., Hutchings, M., Yoon, S.‐S., Koh, Y., Manier, S., Facon, T., Harrison, S. J., Er, J., Volzone, F., Pinto, A., Montes, C., Ocio, E. M., Alfonso‐Pierola, A., Rodriguez Otero, P., Offner, F., Guidetti, A., Corradini, P., Titouan, C., Hulin, C., Touzeau, C., Moreau, P., Popat, R., Leong, S., Mazza, R., Bröske, A.‐M. E., Dekhtiarenko, I., Helms, H.‐J., Belli, S., Vardar, T., Fauti, T., Eckmann, J., Moore, T., Schneider, M., Jacob, W., Weisser, M., Carlo‐Stella, C.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
S182: TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL‐1
Minnema, M. C., Krishnan, A., Berdeja, J. G., Oriol, A., Donk, N. W., Rodríguez‐Otero, P., Morillo, D., Mateos, M.‐V., Costa, L. J., Caers, J., Vishwamitra, D., Ma, J., Yang, S., Hilder, B. W., Tolbert, J., Goldberg, J. D., Chari, A.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
P10: TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL‐1
Donk, N. W. C. J, Minnema, M C, Berdeja, J G, Oriol, A, Krishnan, A, Rodríguez‐Otero, P, Askari, E, Mateos, M, Costa, L. J, Verona, R, Ma, J, Girgis, S, Yang, S, Hilder, B. W, Russell, J, Goldberg, J. D, Chari, A
Published in HemaSphere (01.04.2022)
Published in HemaSphere (01.04.2022)
Get full text
Journal Article
S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB
Donk, N. W., Bahlis, N., Mateos, M.‐V., Weisel, K., Dholaria, B., Garfall, A. L., Goldschmidt, H., Martin, T. G., Morillo, D., Reece, D. E., Hurd, D., Rodríguez‐Otero, P., Bhutani, M., D'Souza, A., Oriol, A., Askari, E., San‐Miguel, J. F., Kortüm, K. M., Vishwamitra, D., Xin Wang Lin, S., Prior, T. J., Vandenberk, L., Smit, M.‐A. D., Goldberg, J. D., Wäsch, R., Chari, A.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article